Long-Lasting Sprouting and Gene Expression Changes Induced by the Monoclonal Antibody IN-1 in the Adult Spinal Cord

Abstract

Lesion-induced plasticity of the rat corticospinal tract (CST) decreases postnatally, simultaneously with myelin appearance. In adult rats, compensatory sprouting can be induced by the monoclonal antibody (mAb) IN-1 raised against the growth inhibitory protein Nogo-A. In this study, we examined separately the fate of sensory and motor corticospinal fibers after mAb IN-1 application. Intact adult rats treated with the IN-1 antibody exhibited an increase of aberrant CST projections, i.e., sensory fibers projecting into the ventral horn and motor fibers projecting dorsally. Unilateral lesion of the CST [pyramidotomy (PTX)] in the presence of mAb IN-1 triggered a progressive reorganization of the sprouting of the remaining CST across the midline, with sensory fibers projecting gradually into the denervated dorsal horn and motor fibers projecting into the denervated ventral horn. In unilaterally denervated spinal cords, aberrant sprouts were only transient and disappeared by 6 weeks, whereas midline crossing fibers ending in the appropriate target region were stabilized and persisted over the entire study period. Within the spinal cord, IN-1 antibody treatment was associated with upregulation of growth factors (BDNF, VEGF), growth-related proteins (actin, myosin, GAP-43), and transcription factors (STATs), whereas pyramidotomy induced an enhanced expression of guidance molecules (semaphorins and slits) as well as neurotrophic factors (BDNF, IGFs, BMPs). These gene expression changes may contribute to attraction, guidance, and stabilization of sprouting CST fibers.

The pyramidal tract, originating in the sensory and motor cortex, is the only direct cortical pathway to the spinal cord. In cats (Fetz, 1968), primates (Coulter and Jones, 1977; Cheema et al., 1984; Ralston and Ralston, 1985), and hamsters (Kuang and Kalil, 1990), a precise topographic organization of sensory and motor fibers projecting into the dorsal and ventral horn of the cord, respectively, has been described. The rodent corticospinal pathway is also a valuable model for studying injury-induced plasticity and compensatory growth originating either from the injured side of the cord in the form of collateral sprouting of spared axons (Kalil and Reh, 1979; Kalil and Reh, 1982; Bernstein and Stelzner, 1983; Schreyer and Jones, 1983; Bregman et al., 1989; Merline and Kalil, 1990; Weidner et al., 2001) or from sprouting axons of the intact contralateral corticospinal tract (CST) (Hicks and D'Amato, 1970; Whishaw and Kolb, 1988; Z'Graggen et al., 2000). Many of these studies observed that substantial spontaneous anatomical reorganization is restricted to lesions occurring in early postnatal life. During development, the massive downregulation of CNS regenerative and plastic capacities coincides with the appearance of myelin and its associated neurite growth inhibitory proteins (Kapfhammer and Schwab, 1994a,b;Steeves et al., 1994). Among several proteins inhibiting neurite outgrowth in CNS myelin is NI-250 (now Nogo-A) (Caroni and Schwab, 1988a,b; Chen et al., 2000). The monoclonal antibody (mAb) IN-1, raised against NI-250, induces regeneration of adult lesioned corticospinal tract (Schnell and Schwab, 1990; Brosamle et al., 2000) and optic nerve fibers (Weibel et al., 1994). The mAb IN-1 also greatly enhances compensatory sprouting in the adult rat: midline crossing corticorubral and corticopontine fibers originating from the intact tract established bilateral projections after unilateral pyramidotomy (PTX) (Z'Graggen et al., 1998), and CST sprouts grew from the unlesioned to the contralateral denervated spinal cord (Thallmair et al., 1998). After bilateral PTX and IN-1 mAb treatment, the number of collaterals from the rubrospinal tract innervating the cervical cord doubled (Raineteau et al., 2001). In all of these cases, IN-1-induced anatomical reorganization was associated with dramatic behavioral improvement. Functional recovery requires precision in the formation and persistence of new neuronal connections; at present, nothing is known about the underlying molecular mechanisms. Thus this study was undertaken to determine the topographic organization of the rat CST, the long-lasting effects of mAb IN-1 treatment on CST fiber sprouting in the absence of, or after a CNS lesion, and the gene expression changes concomitant with the anatomical reorganization.

The present data show that, also in the rat, projections of the sensory and motor cortex terminate precisely within the spinal dorsal and ventral horn, respectively. The mAb IN-1 triggers sprouting of CST fibers in intact rats that is aberrant but transitory. After unilateral PTX, mAb IN-1 induces compensatory sprouting across the midline that is target specific and mostly stable, suggesting lesion-induced CST sprouting and rewiring. The sprouting effect of the IN-1 antibody was associated with increased growth-related protein expression (among others), whereas the PTX-driven compensatory reorganization was paralleled by enhanced expression of certain guidance molecules.

MATERIALS AND METHODS

Male adult Lewis rats (200–220 gm) were used in this study. Anatomical and histochemical data were obtained from 120 animals with successful labeling of the corticospinal axons, and gene expression data were obtained from 30 animals.

Anatomical organization and reorganization of CST projections

Pyramidotomy and antibody application. Rats were anesthetized using a combination of Hypnorm (0.3 mg/kg, s.c; Roche, Basel, Switzerland) and Dormicum (0.6 mg/kg, s.c.; Roche). A right unilateral lesion of the CST at the level of the medulla oblongata was performed by using a ventral approach (Thallmair et al., 1998). Briefly, the right medullary pyramid was exposed through an opening of the occipital bone, and the right CST was transected rostral to the decussation with the basilar artery serving as a landmark for the midline. At the time of surgery, 4 μl of hybridoma cell suspension (10⁵ cells) secreting either the monoclonal antibody IN-1 or an anti-HRP as control antibody (Schnell and Schwab, 1993) was injected into the right hippocampal formation (coordinates: −4 mm caudal, 5 mm lateral to bregma, 5 mm depth). Cyclosporin A (5 mg/kg body weight, i.p.; Sandimmun, Novartis, Basel, Switzerland) was given daily during the first 5 d postoperatively to allow the transplant to grow and secrete the antibody. Pyramidotomized animals receiving no cells were also generated as a control baseline as well as intact animals without pyramidotomy but with antibody transplant only. After surgery, all animals were kept on a heating plate (38°C) until fully awake and received Carpofen (Rimadyl, 5 mg/kg, i.m.; Pfizer, Karlsruhe, Germany) for 2 d.

Anterograde tracing of the sensory and motor CST. Locations of forelimb sensory and motor cortices were determined by measuring positions on the skull relative to bregma (Neafsey et al., 1986). Pressure injections of 600 nl of a 10% solution of biotinylated dextran amine [BDA 10,000, Molecular Probes (Eugene, OR) in 0.01 m phosphate buffer, pH 7.4] were made into either the left forelimb sensory cortex (coordinates: 0.5 mm posterior to bregma, 4.5 mm lateral to bregma, 1.5 mm depth) or the left motor cortex (coordinates: 2 mm anterior to bregma, 3 mm lateral to bregma, 1.5 mm depth) through a glass capillary that remained in its position for 2 min after the end of the injection.

To determine (1) the topographic specificity of corticospinal projections, unlesioned BDA-labeled rats were killed 2 weeks after injection. To determine (2) the temporal reorganization of corticospinal projections after mAb IN-1 administration, animals were killed 1 week, 2 weeks, and 6 weeks after pyramidotomy and hybridoma implantation. Sham-operated animals (laminectomy at the level of the medulla oblongata only) were also generated and served as a baseline. At the time animals were killed, animals were deeply anesthetized with pentobarbital (450 mg/kg, i.p.; Abbott Laboratories, Cham, Switzerland) and perfused transcardially with 100 ml of Ringer's solution containing 100,000 IU/l heparin (Liquemin, Roche, Basel, Switzerland) and 0.25% NaNO₂ followed by 300 ml of 4% paraformaldehyde in 0.1 m phosphate buffer with 5% sucrose. The brains and spinal cords were dissected and postfixed overnight at 4°C in the same fixative. Meninges were removed, and the cervical enlargement was embedded in a gelatin-chicken albumin solution polymerized with 2.5% glutaraldehyde. Fifty micrometer sections were cut in the coronal plane using a Vibratome (Leica vt 1000S). All sections were collected in 50 mm Tris-buffered 0.9% saline, pH 8, and 0.5% Triton X-100 (TBS-Tx). They were serially mounted on Superfrost slides (Superfrost/Plus, Menzel-Gläser, Germany) according to the semifree floating technique (Herzog and Brosamle, 1997). Sections were washed three times for 30 min in TBS-Tx before overnight incubation in avidin–peroxidase in TBS-Tx (ABC elite, Vector Laboratories, Burlingame, CA). The next day, the slides were washed three times for 30 min in TBS-Tx. After an additional wash in 50 mm Tris-HCl, pH 8, a preincubation for 10 min in 0.4% ammonium nickel sulfate (Sigma, St. Louis, MO) was performed, followed by a second preincubation in 0.4% ammonium nickel sulfate and 0.015% 3,3′-diaminobenzidine (DAB; Sigma, Buchs, Switzerland) for 10 min. The tissue was then reacted in 0.4% ammonium nickel sulfate, 0.015% DAB, and 0.004% H₂O₂ in 50 mm Tris buffer, pH 8, for another 10 min. The process was stopped by washing with Tris-HCl buffer. The sections were air dried, counterstained slightly with cresyl violet, and coverslipped with Eukitt (Kindler, Freiburg, Germany).

Quantification of anatomical reorganization. Sensory and motor corticospinal projections were quantified by counting (1) the number of sensory axons sprouting across Rexed's lamina V into the ventral horn or the number of motor axons sprouting across Rexed's lamina V into the dorsal horn and (2) the number of axons conserving their topographic location but sprouting across the midline. Quantification was performed by a blinded observer with respect to the treatment and the injury status. Fibers seen physically crossing the midline were counted using a light microscope at 200× magnification on 40 consecutive sections starting at the standard level C4 (cervical level 4). Quantification of the total number of fibers labeled in the main CST was also performed under light microscopy at 400× magnification in three separate sections to generate a ratio of sprouting fibers for each animal to account for differences in BDA labeling between individual rats.

Quantification of fiber arborizations. Arborization of the fibers was estimated by scoring as follows: 0, no sprouts coming out of the fibers; 1, very few branches per fibers (less than two); 2, branching important but present in <50% of the fibers in the anatomical region; 3, branching important and present in >50% of the fibers; 4, dense branching present in all fibers.

Gene expression changes after IN-1 treatment and pyramidotomy

Pyramidotomy and antibody application. A first group of rats underwent a right-side pyramidotomy as described above. Sham animals with a laminectomy only were generated in parallel. A second group of rats received hybridoma cells secreting either the mAb IN-1 or the anti-HRP control antibody as described above (no lesion). Control animals receiving no cells were generated in parallel as a baseline. A third group of rats were pyramidotomized, and hybridoma secreting either IN-1 or anti-HRP antibodies were implanted. At 48 hr, 1 week, or 4 weeks after injury (n = 3 per group) rats were decapitated, and the spinal cords were quickly dissected on a cold plate. Three millimeter transverse sections were taken at the cervical enlargement, and for the lesion experiments, the lesioned side was separated from the unlesioned side. Samples of three rats per group were pooled, and the tissue was immediately frozen in isopentane (−70°C) and subsequently used for RNA extraction.

Sample preparation and hybridization to oligonucleotide arrays. The procedures described in detail in the Affymetrix GeneChip Expression Analysis Manual (Affymetrix Inc., Santa Clara, CA) were followed. RNA was extracted with TRIzol Total RNA Isolation Reagent (Invitrogen, Rockville, MD), and the RNA purity was checked by spectrophotometry and agarose gel electrophoresis. RNA was cleaned (RNEasy Mini Kit, Qiagen Inc., Valencia, CA) and converted to double-stranded cDNA using an oligo dT primer containing the T7 promoter (Invitrogen Superscript Choice System, Invitrogen). The cDNA was cleaned with phase-lock gel, extracted by phenol/chloroform, ethanol precipitated, and used for biotinylated cRNA preparation (Bioarray High Yield RNA Transcription Labeling Kit, Enzo Diagnostics, Farmingdale, NY). The biotinylated cRNA was cleaned (RNEasy spin columns, Quiagen), quantified, fragmented, and checked by agarose gel electrophoresis. Biotin-labeled cRNA was then hybridized to Affymetrix rat genome U34A GeneChip in Affymetrix fluidics station 400. The chips were washed and stained with streptavidin–phycoerythrin.

Data analysis. The oligonucleotide gene chip used in the present study contains several probe sets specific for rat housekeeping genes (β-actin, GADPH, hexokinase, 5S rRNA) which served as internal controls. Several human, murine, and yeast probe sets on each chip served as negative controls, and externally spiked bacterial bioB, bioC, bioD, and Cre served as positive hybridization controls. The gene chips were scanned with a probe array scanner, and the results were subsequently analyzed using the Affymetrix GeneChip analysis followed by the DNA-Chip Analyzer (dChip) software from Harvard University (Li and Wong, 2001). The Affymetrix GeneChip software conducted the pairwise comparisons among replicate samples. For each treatment group, samples were run in replicate and cross compared, thus generating four pairwise comparisons analyzed with dChip. Fold changes were taken into account only for those genes showing a “fold change” value superior to 1.2 and a p value <0.05.

Validation of the gene chip data: RNase protection assay

The same total RNA extracted previously from spinal cords of IN-1 or anti-HRP-treated rats or control rats for the gene chip analysis was used.

Cloning of rat STAT1, GAP43, vimentin, neurofilament light, and TIMP1 PCR probes. The rat cDNA sequences of STAT1, GAP43, vimentin, neurofilament light (NFL), and TIMP1 were analyzed by using the program Oligo (Primer Analysis Software, Cascade, CO) with regard to their suitability for primer selection. The following primers were used and synthesized (Microsynth, Balgach, Switzerland): GAP43, sense: 5′-CAG CCA CCA GCC CTA AGG-3′, antisense: 5′-TCA GTG ACA GCA GCA GGC-3′; STAT1, sense: 5′-CCA TCC GCT TCC ATG ACC-3′, antisense: 5′-GTT TCT GGT CGC TCT TCG-3′; vimentin, sense: 5′-CCG CAC CTA CAG CCT AGG-3′, antisense: 5′-TCT GCT GCT CGA GGA AGC-3′; TIMP1, sense: 5′-AGC TTC CTG GTT CCC TGG-3′, antisense: 5′-GGT AGC CCT TCT CAG AGC-3′; NFL, sense: 5′-TCG ACC TCC TAC AAG CGG-3′, antisense: 5′-ACC AAC AGC TCG GCT TCC-3′. Riboprobes were transcribed from linearized templates prepared in Bluescript plasmid using the T7 in vitro transcription system (Stratagene) and labeled with ³²P uridine triphosphate.

Isolation and analysis of RNA. Ribonuclease protection assays were performed using the Ribo Quant Kit (PharMingen). For each reaction, probes (4.6 10⁵ cpm) were hybridized against 10 μg of spinal cord RNA and RNase-treated according to the manufacturer's instructions. tRNA was used as negative control. GAPDH was used as an internal standard for the amount and integrity of the RNA preparations. Protected fragments were separated on a 5% sequencing gel. Radioactivity in each band was quantified using a PhosphorImager (Amersham Biosciences). The level of expression of each RNA was calculated as a ratio of the protected RNA fragment to the intensity of the protected GAPDH fragment. The intensity of the GAPDH fragment was roughly equivalent in all the samples, showing that GAPDH expression was independent of any treatment applied. Relative expression values (fold changes) were calculated by dividing the level in antibody-treated rats by the level in control untreated rats. Experiments were performed three to six times.

GAP-43 immunohistochemical staining and analysis

Spinal cord sections were collected and mounted as explained previously. Primary antibodies were used at a dilution of 1:1000 (GAP-43, Chemicon) and 1:40 (vimentin, Chemicon). Immunohistochemistry for each antibody was performed on all sections at the same time. Sections were incubated in methanol containing 5% H₂O₂ to quench endogenous peroxidases, washed in 0.1 m Tris buffer, pH 7.4, and blocked in TBS-T × 5% normal horse serum. All antibodies were diluted in TBS-T × 5% normal horse serum and AB complex in 0.1 m Tris buffer. Sections were incubated overnight with primary antibody at 4°C and incubated at room temperature for 1 hr with appropriate biotinylated secondary antibodies [biotin-SP donkey anti-rabbit IgG (Jackson ImmunoResearch; West Grove, PA; dilution, 1:1000) for polyclonal GAP-43; biotin–SP rabbit anti-goat IgG (Vector Laboratories; dilution, 1:300) for vimentin]. Sections were then incubated at room temperature for 1 hr with AB reagent (Vector Laboratories) and developed with 3,3′-diaminobenzidine (Sigma). Sections were dehydrated and coverslipped. Application of control serum instead of primary antibody on selected sections of rat tissue provided a negative control. Intensity of the stainings was quantified by trained personnel blinded to treatment and injury status of the animals. Under low-power light microscopy, an image of the whole cervical cord was captured by video camera, and the borders of the spinal cord were traced manually. The pixels per area were then automatically calculated using an image analysis software routine (MCID/M4, Imaging Research, St. Catherines, Ontario, Canada) after defining a threshold for the background that was kept identical throughout the analysis. A ratio between animals treated with IN-1 and anti-HRP antibodies was then calculated.

Statistical evaluation

All data were analyzed using a nonparametric Kruskall–Wallis test in cases of multiple comparisons followed by nonparametric Mann–Whitney tests in cases of paired comparisons. Significance was taken at p < 0.05 and indicated with an asterisk.

RESULTS

Specific topographic organization of sensory and motor corticospinal projections in normal rats

Both forelimb sensory and motor cortex give rise to corticospinal axons that reach their target in the gray matter of the cervical enlargement. Most of the corticospinal fibers cross in the pyramidal decussation and enter the ventral region of the dorsal columns (O'Leary and Koester, 1993). When the injection site of BDA was confined to either the sensory or the motor cortex, the corticospinal projections were located in the dorsal horn (laminas II–V) (Fig.1A) or to the ventral horn (laminas V–X) (Fig. 1B), respectively, demonstrating a clear topographic organization of corticospinal arbors with a small overlap in lamina V. Sensory projections in the dorsal horn were much denser than motor projections in the ventral horn and were mainly concentrated in laminas III–V. Projections from the motor cortex terminated most heavily in laminas VI–IX. Motor corticospinal axons were found to arborize and ramify widely to reach the motoneuronal pool. A small ipsilateral ventral component (<5%) was also observed as described previously (Armand, 1982; Joosten et al., 1992; Brosamle and Schwab, 1997).

Fig. 1.

Photomicrographs and camera lucida reconstructions of corticospinal projections to the cervical spinal cord. A, Projections of sensory CST fibers to the dorsal horn as shown by injections of BDA into the sensory cortex.B, Projections of motor CST fibers to the intermediate layers and the ventral horn as shown by injections of BDA into the motor cortex. Scale bar, 250 μm.

Sprouting of corticospinal fibers after monoclonal antibody IN-1 administration in intact adult animals

Animals sustaining a laminectomy without lesion of the pyramid were implanted with either IN-1 or anti-HRP antibody secreting cells, and sensory or motor corticospinal projections in the cervical enlargement were analyzed by comparison to control rats receiving no cells. Quantification of sprouting fibers was conducted 2 weeks after antibody application in two ways: (1) fibers topographically projecting across the midline and (2) fibers aberrantly sprouting across lamina V (i.e., motor fibers entering laminas III and IV and sensory fibers entering laminas VI and VII). When BDA was injected into the sensory cortex, no midline-crossing fibers could be detected in any of the treatment groups. In particular, animals implanted with anti-HRP or IN-1 antibodies were not statistically different (p > 0.05) from control animals (Fig.2A). Similarly, when BDA was injected into the motor cortex, no midline-crossing fibers were observed after anti-HRP antibody treatment (p > 0.05) (Fig. 2B). However, the number of midline-crossing fibers was slightly higher after IN-1 monoclonal antibody treatment (p < 0.05; IN-1 antibody-treated rats vs anti-HRP antibody-treated rats or control rats) (Fig. 2B).

Fig. 2.

Percentage of CST fibers sprouting across lamina V or across the midline in the cervical spinal cord in nonlesioned animals. A, Sensory CST projections. B, Motor CST projections. Monoclonal antibody IN-1 induced both sensory and motor fibers to sprout across lamina V when compared with anti-HRP mAb treatment. In addition, IN-1 induced motor fibers to cross the midline of the spinal cord. *IN-1 or HRP antibody-treated rats significantly different from control non-treated rats (p < 0.05). #IN-1 antibody-treated animals significantly different from anti-HRP antibody-treated rats (p < 0.05). Black diamondsindicate individual values.

When invasion of the ventral horn by sensory fibers was evaluated, no statistical differences were seen between anti-HRP antibody-treated rats and control rats. Conversely, IN-1 antibody-treated rats demonstrated significantly more sensory fibers entering the ventral horn than anti-HRP antibody-treated rats and control rats (p < 0.05 and p < 0.01, respectively (Figs. 2A,3A,B). When motor CST fibers were observed for their ability to invade the dorsal horn, anti-HRP and IN-1 antibody-treated animals showed significantly more ectopic fibers than control animals (p < 0.05 in both cases) (Fig.2B). In addition, IN-1 antibody-treated animals demonstrated a significantly higher (p < 0.05) (Figs. 2B, 3C,D) number of motor CST fibers invading the dorsal horn than anti-HRP antibody-treated animals. These observations show that monoclonal antibody IN-1 induces sprouting of sensory and motor CST fibers in the noninjured adult rat spinal cord.

Fig. 3.

Photomicrographs of fibers sprouting across lamina V in nonlesioned animals. A, No invasion of the ventral horn by sensory fibers after anti-HRP treatment. B, Invasion of the ventral horn by sensory fibers (arrows) after IN-1 treatment. C, No invasion of the dorsal horn by motor fibers after anti-HRP treatment. D, Pronounced invasion of the dorsal horn by motor fibers (arrows) after IN-1 treatment. Scale bar, 250 μm.

Long-term topographic reorganization of adult corticospinal fibers after pyramidotomy and implantation of monoclonal antibody IN-1 secreting cells

The CST was removed unilaterally by transection at the entry into the pyramidal decussation (pyramidotomy). Reorganization of the fibers was assessed 1, 2, and 6 weeks after pyramidotomy in rats implanted with IN-1 or anti-HRP antibody-secreting cells or in control rats (lesion only). As previously, quantification of the sprouting fibers was conducted by counting (1) fibers topographically projecting across the midline and (2) fibers aberrantly sprouting into the inappropriate horn (i.e., motor fibers entering laminas III and IV and sensory fibers entering laminas VI and VII). Because we counted only fibers visibly crossing the midline, we did not include ipsilateral ventral fibers that were also reported by Weidner et al. (2001) to sprout after a CST lesion. In all sprouting parameters examined (i.e., aberrant or across the midline), no significant sprouting of motor or sensory fibers was observed 1 week after pyramidotomy when anti-HRP antibody-treated rats were compared with control rats (Fig.4A–D). Conversely, IN-1 antibody-treated rats demonstrated significantly more motor and sensory fibers crossing the midline at 1 week (Fig.4B,D) when compared with control and anti-HRP antibody-treated rats (p < 0.05 in both cases). IN-1 antibody-treated rats also showed significantly more ectopic motor and sensory fibers invading the dorsal and ventral horns, respectively, by comparison with control rats (p< 0.05) but not anti-HRP antibody-treated rats 1 week after pyramidotomy (Fig. 4A,C).

Fig. 4.

Long-term reorganization of motor (A, B) or sensory (C,D) CST fibers in pyramidotomized animals. IN-1 treatment induced more motor fibers to sprout dorsally (A) and more sensory fibers to invade the ventral horn on the intact side 2 weeks after pyramidal tract lesion than anti-HRP antibody treatment (C). IN-1 also induced motor and sensory fibers to cross the midline 1 and 2 weeks after pyramidal tract lesion, in contrast to anti-HRP treatment (B, D). Sensory sprouts retracted, but motor fibers grew across the midline to the denervated cord and were stable at 6 weeks after injury (B). ∗Anti-HRP-treated rats significantly different from control nontreated rats (p < 0.05). #IN-1 antibody-treated rats significantly different from anti-HRP-treated rats (p < 0.05).

At 2 weeks after injury, anti-HRP antibody-treated animals showed an increased number of sprouting fibers when compared with control animals in all parameters examined (p < 0.05 in all cases) except for ectopic sensory CST projections. IN-1 antibody-treated animals showed significantly more midline crossing fibers than control animals in all parameters examined (p < 0.05 in all cases) (Fig. 4). In addition, IN-1 antibody-treated rats exhibited significantly more sensory and motor fibers topographically crossing the midline to invade the contralateral dorsal and ventral horn, respectively, than anti-HRP antibody-treated animals (p < 0.01) (Fig.5A–D). When aberrant sprouting of sensory fibers (into the ventral horn) was considered, a small but statistical increase was also shown after IN-1 antibody treatment when compared with anti-HRP antibody treatment 2 weeks after pyramidotomy.

Fig. 5.

Photomicrographs of fibers sprouting across the spinal cord midline 2 weeks after pyramidotomy. A, Topographic sprouting of a sensory CST fiber (arrow) into the contralateral, denervated dorsal horn after IN-1 mAb treatment. B, Absence of sprouting of sensory fibers after anti-HRP treatment. C, Topographic sprouting of motor CST fibers into the contralateral ventral horn (arrows) after IN-1 mAb treatment. D, Virtual absence of sprouting (very rare fibers) of motor fibers in anti-HRP treatment. Scale bar, 250 μm.

At 6 weeks after injury, animals treated with anti-HRP antibody were similar to control animals in all parameters examined. Conversely, IN-1 antibody-treated animals exhibited a significantly higher sprouting index when compared with control animals (p < 0.05) in all cases. In addition, IN-1 antibody-treated animals exhibited significantly more motor fibers topographically crossing the midline than anti-HRP antibody-treated animals (p < 0.01), indicating that the sprouts triggered by the antibody IN-1 at 1 or 2 weeks after the lesion were stable over an extended period of time.

Motor corticospinal fibers persist over time and arborize

We estimated the arborization complexity of motor CST fibers grown across the midline into the denervated ventral horn by a 0–4 point score (0, no branches/4, highly branched terminal arbors) at 1, 2, and 6 weeks after pyramidotomy and anti-HRP or IN-1 antibody application. We observed that at 1 and 2 weeks, scores were low, and the branching complexity after IN-1 treatment was not statistically different from the complexity of the rare fibers seen after anti-HRP treatment. Conversely, 6 weeks after the injury, a significantly higher arborization complexity was detected in IN-1 antibody-treated animals when compared with the very few fibers seen after anti-HRP treatment (p < 0.05) (Fig.6), indicating that the persisting fibers acquired a more pronounced complexity (Fig.6A,B).

Fig. 6.

Photomicrographs of the arbor complexity of motor fibers grown across the midline into the denervated ventral horn at 2 weeks (A) and 6 weeks (B) after pyramidotomy and monoclonal IN-1 antibody treatment.C, Complexity of axonal arbors of motor CST fibers 1, 2, and 6 weeks after pyramidotomy and antibody treatment. Six weeks after the injury, IN-1-treated animals had higher scores than anti-HRP-treated animals. Scores are described in Materials and Methods. ∗IN-1-treated rats significantly different from anti-HRP-treated rats (p < 0.05).Black and white diamonds represent individual values. Scale bar, 200 μm.

Gene expression changes in the cervical spinal cord after pyramidotomy and IN-1 monoclonal antibody application

Of 8784 oligonucleotide probe sets present on the Affymetrix U34A chips, 3601–4589 (41–52%) were identified as present in control as well as in injured or antibody-treated rats. Replicate chips, done for each experimental point, gave extremely similar results (R² above 0.95 after paired comparison analysis).

Gene expressions changes in the cervical spinal cord after pyramidotomy: 48 hr and 1 week

In the denervated cervical spinal cord, at 48 hr after pyramidotomy, the major upregulated genes were IGFII, IGF receptor, and binding protein, BMP-2, components of the pro-apoptotic cascade (BAD/caspases/c-jun), some extracellular matrix (ECM) proteins (laminin/decorin/collagen), and enzymes of the cell metabolism (Table 1). Some metabolic genes were also downregulated (lipooxygenase/acyl-coA synthase). At 1 week after pyramidotomy, we found prominent upregulation of growth factors and their receptors (trkB/VEGF receptor/BDNF), the axonal guidance molecules (semaphorin 3/slit1), and ECM proteins (decorin/lumican/collagens). Cytoskeletal proteins (actin/myosin/MAP2), GABA receptors, and several ion transporters (Cl⁻/HCO₃⁻exchanger/NaK ATPase/Ca²⁺ ATPase) were downregulated (Table 1).

Table 1.

Differential gene expression in the cervical cord when the denervated side was compared with the intact side of the cervical spinal cord (3-mm-thick sections; three rats pooled) 48 hr and 1 week after pyramidotomy

Probe set	Gene	Fold change 48 hr	Fold change 1 week
Cell metabolism
M27886	Bifunctional enzyme 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase	2.84
rc_AI012589_s_at	Glutathione S-transferase, pi 2	1.42
J02592_s_at	Glutathione S-transferase, mu type 2 (Yb2)		1.39
J03867_s_at	NADH-cytochrome b-5 reductase		−1.47
M11670_at	Catalase		−1.63
AB002558_at	Glycerol 3-phosphate dehydrogenase		−1.52
D85189	Acyl-CoA synthetase	−2.31
S69383	12-lipoxygenase	−3.53
AA800851	pl 6.1 esterase	−3.59
L06040	12-lipoxygenase	−4.30
Cytoskeletal proteins
J00692_at	α-actin		−2.93
S68736_at	Myosin heavy chain		−3.03
L00088expanded_cds#2_at	Fast myosin alkali light chain		−3.04
X53455	Microtubule-associated protein 2		−4.31
Extracellular matrix proteins
X84039	Lumican		4.03
M21354	Collagen type III alpha-1	2.11	3.17
X70369_s_at	Pro α 1 collagen type III		2.67
Z78279_at	Collagen α 1 type I		2.18
rc_AI639233_s_at	Decorin	2.02
Z12298cds_s_at	Dermatan sulfate proteoglycan-II (decorin)	1.99	2.14
U75405UTR#1_f_at	α 1 type I collagen	1.47
Growth factors/receptors/guidance molecules
M55293	Neural receptor protein-tyrosine kinase (trkB)		25.71
X95286	Semaphorin III/collapsin-1		3.22
U93306	VEGF receptor-2/FLK-1		3.14
S76758	BDNF		2.22
M91595exon_s_at	Insulin-like growth factor binding protein-2	2.03
X17012mRNA_s_at	IGFII gene for insulin-like growth factor II	1.85
L20678_at	Bone morphogenetic protein 2	1.85
AB017170	Slit-1 protein		1.81
M15481_g_at	Insulin-like growth factor I (IGF-I)	1.79
U25650_f_at	Low-affinity NGF receptor precursor		1.56
AB016160_g_at	GABAB receptor 1c		−1.44
AF058795_at	GABA-B receptor gb2		−1.64
Immunological proteins
K02815_s_at	MHC RT1-B region class II (Ia antigen) A-α glycoprotein		1.49
Intracellular cell signaling
AF003523	BAD	2.86
AF072124	Caspase 7	2.85	−2.70
AF025671	Caspase 2	2.13
X17163	c-jun oncogene for transcription factor AP-1	2.02	−2.81
M24104_at	Vesicle-associated membrane protein (synaptobrevin 2)	1.83
M24104_g_at	Vesicle-associated membrane protein (synaptobrevin 2)	1.67
AB003991_at	SNAP-25A		−1.47
S74122	bcl-2=proto-oncogene		−3.2
Ion transport
AF004017_at	Electrogenic Na+ bicarbonate cotransporter		−1.46
J05166	3 Cl-/HCO3-exchanger (B3RP2)		−1.81
D90049	Na+, K+-ATPase (EC 3.6.1.3) α2 subunit gene		−2.45
M99223	Calcium transporting ATPase		−3.02
Schwann cell proteins
Z29649_at	Periaxin	1.96	2.76
S55427_s_at	Myelin protein SR13=growth-arrest-specific Gas-3 homolog	1.77	1.76
Diverse
X07266	Gene 33 polypeptide		−4.10
X59864	ASM15		−8.33
rc_AI231445_at	RNA binding protein		−1.63

Data are presented as fold changes. Only significant changes (>1.2-fold; p < 0.05) using dChip are presented.

Gene expressions altered in the cervical spinal cord after monoclonal antibody IN-1 treatment: 48 hr and 1 week

In the cervical spinal cord, at 48 hr, when unlesioned animals treated with IN-1 were compared with animals treated with anti-HRP antibody, the major upregulated genes were for cytoskeletal proteins (actin/myosin), creatin kinase, and calcium-binding proteins, genes related to inflammation and collagens (Table2). At 1 week, when animals treated with monoclonal antibody IN-1 were compared with animals treated with anti-HRP antibody, cytoskeletal proteins (actin/myosin/troponin), the growth-associated protein GAP-43, and the growth factors (BDNF/VEGF) were upregulated several-fold as were transcription factors (STAT1/MRP14), the SNARE protein VAMP1, synapsin3a, creatine kinase, the inhibitor of metalloproteinases TIMP1, and collagens (Table2). The major downregulated genes were related to immune functions and components of the complement system (Table 2).

Table 2.

Differential gene expression in the cervical cord 48 hr and 1 week after IN-1 or anti-HRP antibody application in intact adult rats

Probe set	Gene	Fold change 48 hr	Fold change 1 week
Cell metabolism
M18668_at	Brain creatine kinase	3.10	41.90
M99223_at	Calcium transporting ATPase	−3.09	5.77
rc_AA900582_at	α-2-macroglobulin		−1.53
M23566exon_s_at	α-2-macroglobulin		−1.73
rc_AA817854_s_at	Mitochondrial cytochrome B		−2.10
Cytoskeletal proteins
J00692_at	α-actin	3.62	32.97
S68736_at	Myosin heavy chain	3.26	11.02
L00088expanded_cds#2_at	Fast myosin alkali light chain	4.19	7.91
M73701_at	Troponin I	−5.26	5.51
X02412_at	Tropomyosin 3, alpha	−1.58
Extracellular matrix proteins
Z78279_at	Collagen α 1 type I	2.68	6.92
Z78279_g_at	Collagen α 1 type I	2.37	5.53
rc_AI231472_s_at	Procollagen α 1 type I	2.17	3.36
Z12298cds_s_at	Dermatan sulfate proteoglycan-II (decorin)	−1.28
rc_AI179399_at	Collagen type V, α 2	−1.33
Growth factors/receptors
S76799_at	BDNF		1.90
L20913_s_at	VEGF		1.80
Growth-related proteins
L21192_at	GAP-43		1.91
Immunological proteins
U50353mRNA_s_at	Neutrophil defensin 3a	1.79	10.11
U16686_at	Defensin 1 precursor	1.92	3.31
M15562_g_at	MHC class II RT1.u-D-α chain		−1.63
K02815_s_at	MHC RT1-B region class II		−1.69
X52477_at	Complement component 3		−1.69
X14254cds_g_at	MHC class II-associated invariant chain		−1.72
M29866_s_at	Complement component C3		−1.73
M15562_at	MHC class II RT1.u-D-α chain		−1.75
X13044_at	CD74 antigen (invariant polypeptide of MHC II antigen-associated)		−1.76
U68272_at	Interferon γ receptor		−2.00
X56596_at	MHC class II antigen RT1.B-1 β-chain		−2.02
X71127_g_at	Complement protein C1q β chain		−2.03
Intracellular cell signaling
rc_AA892553_at	STAT 1		7.11
L18948_at	Intracellular calcium-binding protein (MRP14)	2.49	4.42
AF056704_at	Synapsin 3a		2.40
M24104_g_at	VAMP-1 (synaptobrevin2)		1.83
Diverse
X59864mRNA_g_at	ASM15 gene	3.50	12.74
rc_AI169327_g_at	TIMP 1 (tissue inhibitor of metalloproteinase 1)		5.12
rc_AA957003_at	S100 calcium-binding protein A8 (calgranulin A)	2.56
rc_AA925246_at	Cathepsin K	−2.11
M25490_at	Bone γ-carboxyglutamic acid (Gla) protein (osteocalcin)	−2.21	5.94
rc_AI639532_at	Calmodulin	−2.59
Y07704_g_at	Hypothetical protein		2.08
AA944073_at	Ribosomal protein L41		−1.26
X58389cds_s_at	Ribosomal protein L17		−1.30
X58465mRNA_at	Ribosomal protein S5		−1.35
X78327_at	Ribosomal protein L13		−1.36
X93352_at	Ribosomal protein L10a		−1.36
X62322_g_at	Granulin		−1.49
X52733cds_s_at	Ribosomal protein L27a		−1.51

Data are presented as fold changes. Only significant changes (>1.2-fold; p < 0.05) using dChip are presented. IN-1-treated rats were compared with HRP-treated rats.

Genes altered in the cervical spinal cord after pyramidotomy and IN-1 or anti-HRP antibody treatment: 1 and 4 weeks

At 1 week, when the denervated spinal cord of animals treated with monoclonal antibody IN-1 were compared with the denervated spinal cord of animals treated with anti-HRP antibody, the major upregulated genes were cytoskeletal proteins (MAP2/actin), the growth-associated protein GAP-43, growth factors/receptors (BDNF/TrkB/IGFI and II/GDNF receptor/glia maturation factor/endothelin receptor), semaphorin 3a, ECM, and membrane proteins (NCAM/F3/APP/collagen/laminin/TIMP1), and transcription factors (STATs) (Table3). The major downregulated genes were immune response-related molecules such as MHC Class II and components of the complement system (Table3). At 4 weeks, when the denervated spinal cord of animals treated with monoclonal antibody IN-1 were compared with the denervated spinal cord of animals treated with anti-HRP antibody, only very few gene expression changes were observed. The major upregulated gene was BDNF. Actin and collagen were downregulated (Table 3).

Table 3.

Non-exhaustive differential gene expression in the cervical cord 1 week and 4 weeks after both pyramidotomy and IN-1 or anti-HRP antibody application

Probe set	Gene	Fold change 1 week	Fold change 4 weeks
Cell adhesion molecules
D38492_at	Neural adhesion molecule F3	1.90
rc_AI137246_s_at	NCAM	1.84
M14656_at	Sialoprotein (osteopontin)	−1.43
D00913_g_at	Intercellular adhesion molecule-1	−1.58
Cell metabolism
D10770_s_at	β isoform of catalytic subunit of cAMP-dependent protein kinase	2.65
X13983mRNA_at	α-2-macroglobulin gene exon 1 (and joined CDS)	1.72
L05557cds_at	Plasma membrane calcium ATPase isoform 2	1.71
D00636cds_s_at	NADH-cytochrome b5 reductase	1.59
U75932_at	Protein kinase, cAMP dependent, regulatory, type 1	1.35
X55298_at	Ribophorin II	−1.35
Cytoskeletal protein
X53455cds_s_at	Microtubule-associated protein 2	7.71
rc_AA900769_s_at	α actin	4.72	−1.54
X16623cds_s_at	Neuraxin	2.79
X77934cds_at	Amyloid precursor-like protein 2	2.06
rc_AI029183_s_at	Gap junction protein, α 1, 43 kD (connexin 43)	2.06
U35775_at	γ-adducin	1.56
X05834_at	Fibronectin	−2.03
rc_AA892506_at	Coronin/actin binding protein	−2.21
rc_AA892333_at	α-tubulin	−3.28
Extracellular matrix proteins
U75405UTR#1_f_at	α 1 type I collagen	1.56	−1.61
X94551_at	Laminin γ 1	1.35
rc_AI231472_s_at	Procollagen type 1 α 1	1.34	−1.39
L14851_at	Neurexin III-α	−1.33
S61868_at	Ryudocan=heparan sulfate proteoglycan core protein	−1.41
X67788_at	Ezrin	−1.61
Growth factors/receptors
rc_AA818970_s_at	Endothelin receptor	3.97
M55293	Neural receptor protein-tyrosine kinase (trkB)	2.81
S76799_at	BDNF	2.68	2.13
Z11558_at	Glia maturation factor β	2.55
X57514_at	GABA(A) receptor γ-1	2.36
M15481_g_at	Insulin-like growth factor I (IGF-I)	1.77
AF003825_s_at	GDNF receptor-β	1.76
AF039203UTR#1_at	Corticotropin-releasing factor type 1 receptor	1.55
X17012mRNA_s_at	IGFII gene for insulin-like growth factor II		−1.73
Growth-related proteins
L21192_at	GAP-43	2.59
rc_AA946313_s_at	Secreted acidic cystein-rich glycoprotein (osteonectin)		−1.40
Immunological proteins
X62322_g_at	Granulin	−1.39
M15562_g_at	MHC class II RT1.u-D-α chain	−1.40
X71127_g_at	Complement component 1, q subcomponent, β polypeptide	−1.50
X13044_at	CD74 antigen (invariant polypeptide of major histocompatibility class II	−1.51	−1.36
	antigen-associated)
X61381cds_s_at	Interferon	−1.62
rc_AA892775_at	Lysozyme	−1.69
X56596_at	MHC class II antigen RT1.B-1 β-chain	−1.92
M34253_g_at	Interferon regulatory factor 1	−3.99
rc_AA799861_at	Interferon regulatory factor 7	−5.17
U42719_at	C4 complement protein		−1.42
Intracellular cell signaling
rc_AA892553_at	STAT1	3.23
X95286	Semaphorin III/collapsin-1	2.97
D14425_s_at	Calcineurin B	1.87
M24104_g_at	VAMP-1 (synaptobrevin 2)	1.58
rc_AA894317_s_at	Chimerin 1	1.49
AB003991_at	SNAP-25A	1.47
M31178_at	Calbindin D28	1.44
U39875_at	Calcium binding protein P22	1.43
AF009603_at	SH3p4	1.41
M83676_at	RAB12, member RAS oncogene family	1.38
X91810_at	STAT3	1.25
U90312_at	Synaptojanin II	−1.48
rc_H31839_at	bak/bcl2 antagonist	−1.91
L33869_at	Ceruloplasmin (ferroxidase)	−1.96
rc_AI176658_s_at	HSP27	−2.23
rc_AI102562_at	Metallothionein 1	−4.56
X17053mRNA_s_at	Immediate-early serum-responsive JE gene	−5.61
AB012234_at	NF1-X1		−1.37
Ion transport
AF086758_g_at	Na-K-2Cl cotransporter (Nkcc1)	7.83
U14007_at	Aquaporin 4	3.19
D90048exon_g_at	Na+, K+-ATPase	2.50	−1.54
U28975mRNA#2_g_at	Glycine transporter (GLYT-1)	2.41
U27558_at	Brain-specific inwardly rectifying K+ channel 1	2.38
AF004017_at	Electrogenic Na+ bicarbonate cotransporter (NBC)	1.87
S75687_s_at	Glutamate/aspartate transporter	1.65
AF021923_at	Potassium-dependent sodium-calcium exchanger (NCKX2)	1.63
M26161_at	Potassium channel protein	−1.41
X83585cds_s_at	Inward rectifier 10		−1.71
Myelin proteins
D28110_g_at	Myelin-associated/oligodendrocytic basic protein-81	1.40
Schwann cell proteins
Z29649_at	Periaxin	1.80
Diverse
rc_AI169327_g_at	TIMP1 (tissue inhibitor of metalloproteinase)	3.37
L18889_at	Calnexin	1.41
rc_AI012275_at	tpo1-developmentally regulated protein in oligo	1.37
rc_AA799494_at	Hypothetical protein	1.33
rc_AA892123_at	Ribosomal protein L36	−1.35
rc_AA893869_g_at	Hypothetical protein	−1.56
AF065438_at	Mama mRNA	−1.88
rc_AI639117_s_at	Kallikrein	−3.14
U17035_s_at	mob-1	−6.79
Y07704_at	Hypothetical protein	−10.24
X05472cds#2_at	2.4 kb repeat DNA right terminal region		−1.68

Data are presented as fold changes. Only significant changes (>1.2-fold; p < 0.05) using dChip are presented. Denervated cervical spinal cord from IN-1-treated rats were compared with denervated cervical cord from anti-HRP-treated rats.

RNase protection assays

RNase protection assays confirmed the increased expression of GAP-43, TIMP1, and STAT1 and the unaltered expression of NFL and vimentin in rats treated for 7 d with mAb IN-1 compared with anti-HRP antibody (Fig. 7). The magnitude of the changes between control antibody and IN-1 antibody-treated rats were in the same range as those found with the gene chip technology for most of the studied genes.

Fig. 7.

Results from RNase protection assays done on cervical spinal cord tissue and compared with results from the analysis with the Affymetrix gene chip. Five different genes were similarly expressed using both assays in rats treated with mAb IN-1 for 7 d compared with rats treated with an anti-HRP antibody.

Immunoreactivity of GAP-43 after pyramidotomy and IN-1 and anti-HRP antibody treatments

We quantified the immunoreactivity of the growth-related protein GAP-43 and of vimentin in the cervical cord after IN-1 or anti-HRP treatments in unlesioned rats and in rats 1, 2, and 6 weeks after pyramidotomy. IN-1 antibody-treated animals exhibited a twofold increase in GAP-43 immunoreactivity in unlesioned animals as well as 1 and 2 weeks after the lesion and IN-1 antibody treatment when compared with their matching controls (Fig. 8). No differences in GAP-43 immunoreactivity were found 6 weeks after the lesion when IN-1 antibody-treated animals were compared with anti-HRP animals. Vimentin immunoreactivity was unchanged for the entire study period when IN-1 antibody-treated animals were compared with anti-HRP antibody-treated animals.

Fig. 8.

Photomicrographs of GAP-43 immunoreactivity in the denervated cervical spinal cord. IN-1 antibody treatment (B) increased GAP-43 immunoreactivity (twofold by densitometry) in unlesioned animals when compared with unlesioned animals treated with anti-HRP antibody (A). GAP-43 immunoreactivity was also increased (2.5-fold) 2 weeks after pyramidotomy and IN-1 antibody treatment (D) compared with lesioned anti-HRP antibody-treated rats (C). Scale bar, 850 μm.

DISCUSSION

The present results show that the monoclonal antibody IN-1 induces transitory sprouting of CST fibers in the normal adult rat spinal cord associated with enhanced gene expression in particular of cytoskeletal and growth-related proteins and transcription factors. The IN-1 antibody combined with a discrete unilateral pyramidal tract lesion further enhanced the sprouting, especially of motor CST fibers, which formed stable, highly branched projections in the denervated ventral horn. This reorganization was associated with an upregulation of genes such as growth factors/receptors and guidance molecules.

The corticospinal tract is topographically organized

Electrophysiological mapping of the rat sensorimotor cortex has shown a clear topographic organization of somatosensory and motor areas (Donoghue and Wise, 1982; Neafsey et al., 1986), despite regions of overlap of both forelimb and hindlimb representations. Anatomically, the somatosensory and motor cortices can be distinguished in several species by the fact that their corticospinal arbors project differentially within the gray matter of the spinal cord. In the cat, monkey, and opossum (Cheema et al., 1984; Ralston and Ralston, 1985), axons from somatosensory cortex terminate primarily in the dorsal horn, whereas corticospinal axons from the motor cortex terminate most heavily within the ventral horn on interneurons and also on motoneurons (Liu and Rouiller, 1999). The present study demonstrates that also in adult rats, somatosensory and motor cortex are clearly separated anatomically, as reflected by their spinal projections. Contradicting earlier anatomical data for adult rats (Jones et al., 1982; Schreyer and Jones, 1982; Bernstein and Stelzner, 1983; Casale et al., 1988) and hamster (Reh and Kalil, 1981) done with less sensitive tracers and showing that CST fibers terminate most heavily in the medial region of the dorsal horn, more sparsely in the intermediate zone, and not at all in the immediate vicinity of the motoneurons, our present observations are in agreement with the data of Wise and Donoghue (1986) and Liu and Rouiller (1999) showing extensive projections from the motor cortex to intermediate layers of the spinal cord and the region of the motoneuronal pools. Similarly, in hamsters, Kuang and Kalil (1990)demonstrated that somatosensory cortical projections were located in the dorsal horn in the medial half of laminas III, IV, and V and that motor CST projections were located in the ventral horn extending up to the pool of motoneurons.

The monoclonal antibody IN-1 enhances sprouting in normal adult spinal cord

The monoclonal antibody IN-1, raised against the growth inhibitory protein Nogo-A (Caroni and Schwab, 1988a; Spillmann et al., 1998; Chen et al., 2000), is able to selectively and significantly enhance sprouting of sensory and motor corticospinal fibers in normal rat spinal cord. We verified the ability of the hybridoma to secrete large amounts of antibody in vivo by measuring the IN-1 antibody titers in the blood; they were found in all animals tested to be ∼6 μg/ml 1 week after cell implantation. It could also be possible that, by binding to myelin, the antibody initiates a complement-mediated injury to oligodendroglia. We confirmed that no damages attributable to inflammatory processes were observed by performing immunohistochemical stainings for macrophages (OX42) and microglia (ED1). Using similar IN-1 hybridoma grafts or IN-1 Fab pumps, evidence of IN-1-induced axon regrowth and compensatory sprouting was obtained in spinal cord- or brainstem-lesioned animals (Schnell and Schwab, 1990; Schwab and Bartholdi, 1996; Thallmair et al., 1998; Z'Graggen et al., 1998;Raineteau et al., 1999, 2001; Brosamle et al., 2000). Buffo et al. (2000) then demonstrated that in intact animals, a single injection of IN-1 antibody Fab fragment or of an antiserum against Nogo-A was able to induce aberrant profuse but transitory sprouting of Purkinje axons in the granular layer of the cerebellum with a concomitant upregulation of specific growth-associated markers (Zagrebelsky et al., 1998). Here we observe that in the spinal cord, IN-1-induced sprouting of intact CST axons typically displays sensory fibers growing into the ventral horn and motor fibers projecting dorsally and slightly across the midline. However, the presence of these ectopic and aberrant fibers did not seem to impair the gross behavior of the animals. With respect to the mode of action of the IN-1 antibody, interesting hints were provided by the Affymetrix gene chip analysis. Hence, GAP-43 mRNA and protein levels were upregulated in unlesioned IN-1 antibody-treated animals compared with unlesioned anti-HRP antibody-treated rats or untreated controls. Klein et al. (1999) showed that enhanced expression of GAP-43 by somatic gene transfer was associated with axonal sprouting and the formation of aberrant terminal clusters in the nigrostriatal and septohippocampal pathways. IN-1 administration was also associated with the upregulation within the spinal cord environment (intrinsic spinal neurons and glial cells) of transcription factors such as STAT1 and to a lesser extent STAT3. Several reports have shown that the STAT family of transcription factors was expressed after peripheral but not central axotomy and therefore could play a role in signal transduction and regulation of gene activity during peripheral nerve regeneration (Rajan et al., 1995; Yao et al., 1997;Schwaiger et al., 2000). We hypothesize that the mAb IN-1, raised against the growth inhibitor Nogo-A, leads to the activation of the growth program of adult CNS neurons as reflected by an increased transcription of genes such as STATs, GAP-43, actin, and myosin and by sprouting of axons.

The mAb IN-1 enhances long-term compensatory sprouting after unilateral lesion of the pyramidal tract

After unilateral pyramidotomy in adult rats and subsequent treatment with the mAb IN-1, sprouting of the remaining, intact corticospinal tract has previously been observed (Thallmair et al., 1998). Here we show a time course of the initial, more random (sensory vs motor territories), sprouting followed by retraction and compensatory anatomical reorganization that respects the previously described topographic organization. Fiber growth most probably evolved from more random to more precise and topographically organized patterns, in addition to being attracted by the denervated targets. Thus, sensory fibers normally projecting into the dorsal horn grew across the midline to specifically reinnervate the denervated dorsal horn, and motor fibers sprouted across the midline to reinnervate the denervated ventral horn. Some of the sensory fibers were lost between 2 and 6 weeks, but the motor fibers were fully retained and elaborated their arbors. Surprisingly, we observed that the control anti-HRP antibody could also trigger a slight and transient sprouting of fibers in some conditions. This is likely to be attributable to the hybridoma grafts. However, even if we cannot dismiss this nonspecific component, the virulence of the anti-HRP-secreting cells was higher than that of IN-1 hybridomas, emphasizing the specificity of the IN-1-mediated sprouting. Moreover, even if anti-HRP treatment was able to induce sprouting of unlesioned fibers, it has never been reported that it could increase long-distance regeneration of lesioned fibers. This underscores the specificity of IN-1 in inhibiting Nogo-A and allowing the environment to be more permissive for axonal growth.

The presence of specific molecular cues appearing in the spinal cord as a consequence of the denervation was fully confirmed by the Affymetrix gene chip analysis. In addition to growth-related proteins (GAP-43), growth factors (BDNF, VEGF), and transcription factors (STATs) that were upregulated after IN-1 treatment alone, guidance molecules from the semaphorin (3 and 6) and slit family, additional growth factors and receptors (IGFs, BMPs, GDNF receptor) were upregulated after a pyramidotomy. As reflected by the gene expression pattern after combined pyramidotomy and IN-1 cell implantation, it seems likely that two mechanisms must be present for a meaningful compensatory reorganization of CST fibers across the midline of the spinal cord: the more general growth promoting effects of the IN-1 antibody and the denervation-induced modulation of guidance molecules and growth factors that allow fibers to reinnervate denervated target in an organized manner. In this plasticity model, the appearance of target-specific guidance information generated by the lesion seems to channel sprouting axons to reinnervate denervated targets as previously reported in regeneration studies (Wizenmann et al., 1993).

In conclusion, we demonstrated the clear endogenous sprouting effect of IN-1 antibody that, in combination with a unilateral lesion of the pyramids, greatly enhances the compensative capacity of adult motor CST fibers to reorganize in a target-specific manner. Such processes will be of importance for long-term functional recovery after CNS lesion.